CASI Pharmaceuticals Company Profile (NASDAQ:CASI)

About CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals logoCASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CASI
  • CUSIP: N/A
  • Web:
  • Market Cap: $112.57 million
  • Outstanding Shares: 60,196,000
Average Prices:
  • 50 Day Moving Avg: $1.07
  • 200 Day Moving Avg: $1.12
  • 52 Week Range: $0.91 - $1.99
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.28 per share
  • Price / Book: 6.57
  • EBIDTA: ($8,400,000.00)
  • Return on Equity: -46.41%
  • Return on Assets: -32.99%
  • Current Ratio: 7.92%
  • Quick Ratio: 7.92%
  • Average Volume: 41,866 shs.
  • Beta: 0.8
  • Short Ratio: 4.17

Frequently Asked Questions for CASI Pharmaceuticals (NASDAQ:CASI)

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.01. View CASI Pharmaceuticals' Earnings History.

When will CASI Pharmaceuticals make its next earnings announcement?

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for CASI Pharmaceuticals.

Where is CASI Pharmaceuticals' stock going? Where will CASI Pharmaceuticals' stock price be in 2017?

2 analysts have issued twelve-month price targets for CASI Pharmaceuticals' stock. Their predictions range from $2.00 to $4.00. On average, they anticipate CASI Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for CASI Pharmaceuticals.

Who are some of CASI Pharmaceuticals' key competitors?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the folowing people:

  • Wei-Wu He Ph.D., Chairman of the Board
  • Ken K. Ren Ph.D., Chief Executive Officer, Director
  • Cynthia Wong Hu J.D., Chief Operating Officer, General Counsel, Secretary
  • Sara B. Capitelli CPA, Vice President - Finance, Principal Accounting Officer
  • Rong Chen M.D., Ph.D., Chief Medical Officer
  • Tak W. Mak Ph.D., Director
  • Rajesh C. Shrotriya M.D., Director
  • James Z. Huang, Independent Director
  • Franklin C. Salisbury Jr., Independent Director
  • Y. Alexander Wu Ph.D., Independent Director

Who owns CASI Pharmaceuticals stock?

CASI Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wellington Shields Capital Management LLC (1.21%), Wellington Shields & Co. LLC (0.84%), Vanguard Group Inc. (0.48%) and California Public Employees Retirement System (0.23%). Company insiders that own CASI Pharmaceuticals stock include Byte Ltd Sparkle, China Growth Fund Idg-Accel II, Cynthia W Hu, Ken Ren, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals.

Who sold CASI Pharmaceuticals stock? Who is selling CASI Pharmaceuticals stock?

CASI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Wellington Shields Capital Management LLC. View Insider Buying and Selling for CASI Pharmaceuticals.

How do I buy CASI Pharmaceuticals stock?

Shares of CASI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI Pharmaceuticals stock can currently be purchased for approximately $1.84.

MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  66 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CASI Pharmaceuticals (NASDAQ:CASI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (63.04% upside)

Analysts' Ratings History for CASI Pharmaceuticals (NASDAQ:CASI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017HC WainwrightReiterated RatingBuy$2.00MediumView Rating Details
9/8/2017Maxim GroupReiterated RatingBuy$4.00HighView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)
Earnings by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)
Earnings History by Quarter for CASI Pharmaceuticals (NASDAQ CASI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/14/2017Q2 2017($0.03)($0.04)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.04)($0.03)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.07)($0.05)$0.50 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.08)($0.03)ViewN/AView Earnings Details
8/15/2016Q2($0.04)($0.08)ViewN/AView Earnings Details
5/13/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
3/28/2016Q415($0.03)($0.05)$0.03 millionViewN/AView Earnings Details
11/13/2015Q315($0.07)($0.05)$0.10 millionViewN/AView Earnings Details
8/14/2015Q215($0.06)($0.06)$0.27 million$0.02 millionViewN/AView Earnings Details
11/14/2014Q314($0.07)ViewN/AView Earnings Details
8/14/2014Q214($0.06)ViewN/AView Earnings Details
5/15/2014Q114($0.05)($0.05)ViewN/AView Earnings Details
3/21/2014Q413($0.05)$0.67 millionViewN/AView Earnings Details
11/13/2013Q3($0.05)($0.05)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.07)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.02)$1.93 million$0.67 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CASI Pharmaceuticals (NASDAQ:CASI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.03)($0.03)($0.03)
Q3 20171($0.04)($0.04)($0.04)
Q4 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)


Dividend History for CASI Pharmaceuticals (NASDAQ:CASI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CASI Pharmaceuticals (NASDAQ:CASI)
Insider Ownership Percentage: 13.01%
Institutional Ownership Percentage: 3.82%
Insider Trades by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)
Institutional Ownership by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)
Insider Trades by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Wei-Wu HeDirectorBuy315,327$1.33$419,384.91View SEC Filing  
10/28/2016Spectrum Pharmaceuticals IncMajor ShareholderBuy1,789,062$0.01$17,890.62View SEC Filing  
10/3/2016Wei-Wu HeDirectorBuy1,871,605$1.19$2,227,209.95View SEC Filing  
6/24/2016Byte Ltd SparkleMajor ShareholderBuy3,753,855$1.19$4,467,087.45View SEC Filing  
3/7/2016China Growth Fund Idg-Accel IIMajor ShareholderBuy972,708$2.40$2,334,499.20View SEC Filing  
1/19/2016Cynthia W. HuCOOBuy16,800$0.72$12,096.00View SEC Filing  
1/19/2016Ken RenCEOBuy15,000$0.73$10,950.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CASI Pharmaceuticals (NASDAQ:CASI)
Latest Headlines for CASI Pharmaceuticals (NASDAQ:CASI)
DateHeadline logoCASI Pharmaceuticals, Inc. (CASI) Director Buys $419,384.91 in Stock - September 18 at 7:22 PM logoCASI Pharmaceuticals, Inc. (CASI) Stock Rating Upgraded by ValuEngine - September 15 at 9:50 PM logoHC Wainwright Reaffirms Buy Rating for CASI Pharmaceuticals, Inc. (CASI) - September 8 at 6:44 PM logoCASI Pharmaceuticals' (CASI) Buy Rating Reiterated at Maxim Group - September 8 at 1:16 PM logoBRIEF-CASI provides pipeline development update - September 7 at 4:41 PM logoCASI Provides Pipeline Development Update - September 7 at 4:41 PM logoCASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference - September 6 at 4:58 PM logoCASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference - September 6 at 4:58 PM logo-$0.04 EPS Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter - August 18 at 10:18 PM logoCASI Pharmaceuticals, Inc. (CASI) Issues Quarterly Earnings Results - August 15 at 9:41 AM logoCASI Pharmaceuticals Reports Second Quarter 2017 Financial Results - August 14 at 5:23 PM logoMaxim Group Analysts Give CASI Pharmaceuticals, Inc. (CASI) a $4.00 Price Target - August 14 at 1:06 PM logoCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Scheduled to Post Earnings on Monday - August 7 at 7:50 AM logoValuEngine Lowers CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to Sell - July 22 at 9:04 AM logoBrokers Issue Forecasts for CASI Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:CASI) - July 17 at 8:10 AM logoCASI Pharmaceuticals, Inc. (CASI) Upgraded by ValuEngine to "Hold" - July 16 at 4:34 PM logoCASI Pharmaceuticals, Inc. Expected to Earn Q3 2017 Earnings of ($0.04) Per Share (NASDAQ:CASI) - July 14 at 9:48 AM logoZacks: Brokerages Anticipate CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to Post -$0.04 Earnings Per Share - July 7 at 12:24 PM logo-$0.04 Earnings Per Share Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter - June 13 at 12:32 PM logoCASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC) - May 30 at 12:12 PM logoCASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer - May 18 at 11:19 AM logoCASI Pharmaceuticals Inc (CASI) Given a $4.00 Price Target by Maxim Group Analysts - May 17 at 6:32 PM logoCASI Pharmaceuticals Inc (CASI) Expected to Post Earnings of -$0.04 Per Share - May 16 at 8:14 PM logoCASI Pharmaceuticals Inc (CASI) Issues Quarterly Earnings Results - May 16 at 3:48 PM logoBRIEF-Casi Pharmaceuticals reports Q1 loss per share $0.03 - May 15 at 3:48 PM logoCASI Pharmaceuticals Reports First Quarter 2017 Financial Results - May 15 at 11:13 AM logoCASI Pharmaceuticals (CASI) Receives Media Sentiment Score of 0.44 - May 2 at 12:24 PM logoSomewhat Positive Media Coverage Very Unlikely to Affect CASI Pharmaceuticals (CASI) Share Price - April 27 at 6:55 PM logoZacks: Brokerages Expect CASI Pharmaceuticals Inc (CASI) Will Announce Earnings of -$0.04 Per Share - April 26 at 8:19 AM logoCASI Pharmaceuticals (CASI) Earns Media Sentiment Score of 0.44 - April 21 at 2:03 PM logoCASI Pharmaceuticals Inc (CASI) Short Interest Update - April 21 at 10:21 AM logoCASI Pharmaceuticals (CASI) Receiving Favorable Media Coverage, Study Shows - April 18 at 1:37 PM logoMaxim Group Reiterates "Buy" Rating for CASI Pharmaceuticals Inc (CASI) - April 17 at 9:48 AM logoCASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer - April 14 at 11:01 AM logoVery Positive News Coverage Somewhat Likely to Effect CASI Pharmaceuticals (CASI) Share Price - April 14 at 10:50 AM logoFY2017 Earnings Estimate for CASI Pharmaceuticals Inc (CASI) Issued By Zacks Investment Research - April 7 at 5:49 PM logoCASI Exited Fiscal 2016 with a Strong Balance Sheet - April 7 at 8:49 AM logoZacks Investment Research Weighs in on CASI Pharmaceuticals Inc's FY2021 Earnings (CASI) - April 6 at 5:37 PM logoCASI Pharmaceuticals Inc (CASI) Given "Buy" Rating at Maxim Group - April 6 at 8:10 AM logoCASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results - March 31 at 4:18 PM logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition - March 31 at 4:18 PM logoCASI Pharmaceuticals Inc (CASI) Stock Rating Reaffirmed by Maxim Group - March 31 at 1:43 PM logoCASI Pharmaceuticals Announces Poster Presentations At AACR ... - PR Newswire (press release) - March 29 at 12:29 PM logoCASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting - March 28 at 12:51 PM logoCASI Pharmaceuticals Inc (CASI) Set to Announce Earnings on Monday - March 24 at 8:43 PM logoKen Keyong Ren M.D., Ph.D. - January 5 at 9:33 PM logoBRIEF-Casi Pharmaceuticals Inc entered into amendment with Talon Therapeutics - December 17 at 9:20 PM logoCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E - December 16 at 9:34 PM logo7:25 am CASI Pharma announces that China's FDA has accepted for review the Company's import drug registration application for EVOMELA for Injection - December 5 at 4:56 PM logoCASI Pharma's (CASI) Registration App for EVOMELA Accepted by China's FDA - December 5 at 12:30 PM



CASI Pharmaceuticals (CASI) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff